# WindRose Health Investors

WindRose Health Investors is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2000
- **Assets under management:** Undisclosed
- **Website:** windrose.com
- **LinkedIn:** https://www.linkedin.com/company/windrose-health-investors

## Regulatory record

- **CRD number:** 160311
- **SEC file number:** 801-73671
- **Registration status:** APPROVED
- **Latest Form ADV filing:** 2026-05-05T05:00:00.000Z
- **Reports private funds:** Yes
- **Private funds reported:** 0
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/160311

## About

WindRose Health Investors is an SEC-registered investment adviser in NEW YORK, NY, registered since 2012. The firm manages approximately $7.0 billion in regulatory assets. It has 22 employees and 17 investment advisers.

## Sectors

- Healthcare Services
- Digital Health
- Pharma Services
- MedTech

## People

- C.J. Driessen — Managing Partner
- Oliver Moses — Managing Partner
- Grant Chamberlain — Managing Director

## Questions

### Who runs investment decisions at WindRose Health Investors?

Investment decisions are led by Managing Partners C.J. Driessen and Oliver Moses, who co-founded the firm in 2000. Grant Chamberlain, a Managing Director, also serves on the senior investment team. The partnership group has remained small and stable, a deliberate structural choice that concentrates decision-making authority in a team whose entire careers have focused on healthcare investing.

### Does WindRose invest in biotechnology or pharmaceutical drug development?

No. WindRose does not invest in pre-revenue biotech, pharmaceutical drug development, or clinical-stage life sciences companies. Its investment focus is on healthcare services, pharmaceutical services and outsourcing, and medical technology products — businesses with established reimbursement models and existing revenue streams. The firm explicitly targets middle-market companies with $10 million to $50 million of EBITDA rather than unproven science.

### What investment stages does WindRose typically target?

The firm targets control-oriented growth equity and buyout investments in established middle-market healthcare companies. It does not participate in venture capital or seed-stage investing. WindRose's typical platform investment involves acquiring a controlling interest in a profitable North American healthcare business with existing management teams, then pursuing add-on acquisitions to build scale.

### Does WindRose participate in fund commitments or only direct deals?

WindRose executes direct platform investments and add-on acquisitions. Historically, the firm has not operated as a fund-of-funds or allocated capital to third-party healthcare PE funds. Its limited partnership agreements focus capital deployment on direct control positions in operating companies, though co-investment alongside other sector-specialist PE firms occasionally occurs on larger transactions.

### What drove the scale increase between WindRose Fund V and Fund VI?

WindRose Health Investors VI closed at approximately $1.5 billion in January 2025, exceeding its $1.2 billion target and representing a material step up from Fund V's $1.2 billion hard cap reached in 2021. The oversubscribed final close resulted from strong demand among existing institutional LPs seeking additional healthcare specialization and from the firm's realization track record in provider services and pharma outsourcing platforms over the preceding cycle.

## Related profiles

- [Windrose Capital](https://altss.com/profile/windrose-capital)
- [WindSail Capital Group](https://altss.com/profile/windsail-capital-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/windrose-health-investors

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology